Segmed Sets Stage for Growth with David Gascoigne as New CEO

Segmed's Leadership Transition: David Gascoigne Takes the Helm as CEO

Segmed, Inc., renowned for its pioneering work in real-world imaging data crucial for research and artificial intelligence, has officially appointed David Gascoigne as its new Chief Executive Officer. This strategic decision, announced on May 13, 2025, signals a critical juncture for the company as it ramps up its efforts towards innovation and expansion.

David Gascoigne comes into this pivotal role armed with over three decades of experience at the complex intersection of healthcare, life sciences, AI, and real-world data. His notable entrepreneurial background showcases his ability to build and scale businesses, having previously served as the CEO of Almaden Genomics. There, he played an instrumental role in launching a cloud-based, no-code genomics platform, marking a significant advancement in genomic data analysis accessibility for various stakeholders including researchers and biotech firms.

Gascoigne’s previous executive experience spans multiple prominent institutions. His leadership roles include General Manager at IQVIA, Executive Vice President at Symphony Health, Senior Vice President at Sutherland Global Services, Chief Operating Officer at GNS Healthcare, and Partner in Digital Analytics at Accenture. With a robust background in applied statistics from the University of Sheffield in the UK, Gascoigne is uniquely positioned to lead Segmed through its next phase of growth and operational excellence.

In a complementary move, Segmed’s co-founder Dr. Martin Willemink transitions to the role of Chief Scientific Officer. With a strong foundation in cardiovascular imaging research and a prolific publication record, Dr. Willemink has demonstrated exceptional leadership in fostering the company's growth during his tenure as CEO. He has led Segmed through multiple rounds of financing while establishing significant data partnerships worldwide and enhancing the company's AI-ready data platform.

Adding to Segmed's leadership team, Dr. Yin Ho joins as Independent Director. A physician-turned-entrepreneur, Dr. Ho brings over 25 years of extensive experience in healthcare IT and clinical research. She previously held the position of interim CEO at Veradigm, shaping visions for training in-house AI models that transmute Electronic Health Record (EHR) data into actionable clinical research insights. Dr. Ho's strategic leadership has been pivotal in transforming the healthcare IT landscape, positioning her as a game-changer for Segmed.

As the new CEO, Gascoigne expressed his honor in joining Segmed at such a crucial time. He acknowledged the impressive foundation laid by his predecessors and shared his enthusiasm for collaborating with Dr. Willemink and the entire team to enhance Segmed's impact in healthcare through improved data accessibility and innovative partnerships.

Segmed has, since its inception in 2019, aimed to spur innovation in healthcare by providing extensive access to diagnostic-grade medical imaging data. The company is poised for accelerated growth following its Series A financing, and this transition in leadership is set to amplify its operational effectiveness while solidifying its role as a thought leader in the medical imaging and AI landscapes.

The evolving leadership structure not only aims to push forward Segmed's strategic goals but also places an emphasis on promoting collaboration within the scientific community. With Gascoigne’s appointment, Segmed is dedicated to pushing the frontiers of what is possible at the nexus of healthcare data and technology, ensuring that real-world data is harnessed effectively to enhance healthcare delivery and patient outcomes.

The transition in leadership is a reflection of Segmed's commitment to refining its strategic vision and extending its reach within the healthcare sector. As Gascoigne, Dr. Willemink, and Dr. Ho work together toward a shared goal, they strive to make high-quality medical imaging data readily accessible for innovative healthcare solutions—a mission that stands to benefit researchers, clinicians, and patients alike. For more information about Segmed and its initiatives, visit Segmed's Website or follow them on LinkedIn @segmed-ai.